StockMirror — Stock Screener

NGLFINE Q4 FY26 Results & Earnings Analysis

Sentiment: Good (Confidence: medium)

Earnings Summary

NGL Fine-Chem delivered a strong recovery in FY26 with revenue up 36% YoY to ₹500.95cr and EBITDA margin expanding 531 bps to 14.51%. Q4 FY26 was particularly strong (+57% YoY revenue, +769 bps EBITDA margin). The recovery is volume-led and broad-based across geographies. Phase I capacity is operational; Phase II commissioning is slightly delayed to Q2 FY27. Partial price pass-through has been achieved, and management targets 15-18% EBITDA margins going forward. Regulated market (Europe, US) contributions are expected from H2 FY27 and FY28 respectively. Competitive intensity remains high, but product pipeline expansion (10 new APIs/year) and regulatory progress provide growth levers. Key near-term risks include input cost volatility, forex movements, and regulatory timelines.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management emphasized volume-led growth while targeting EBITDA margin improvement to 15-18% range. They are balancing growth investments (capacity expansion, regulatory filings) with margin discipline.

About NGL Fine-Chem Limited

NGL Fine-Chem Limited (NGLFINE) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More